Bicalutamide and third-generation aromatase inhibitors in testotoxicosis

Anne M. Lenz, Dorothy Shulman, Erica A. Eugster, Samar Rahhal, John S. Fuqua, Ora H. Pescovitz, Katherine A. Lewis

Research output: Contribution to journalArticle

30 Scopus citations


Testotoxicosis, a form of gonadotropin-independent precocious puberty, results from an activating mutation of the luteinizing hormone receptor expressed in testicular Leydig cells. Affected males experience early testosterone secretion, virilization, advancing bone age, and resultant short stature. Recently, the use of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term results. We present here the results of longer-term treatment (4.5 and 5 years) with this combination therapy in 2 boys who demonstrated that it is well tolerated, slows bone-age advancement in the face of continued linear growth, and prevents progression of virilization.

Original languageEnglish (US)
Pages (from-to)e728-e733
Issue number3
StatePublished - Sep 1 2010


  • Age determination by skeleton
  • Aromatase inhibitors
  • Bicalutamide
  • Gonadal disorders
  • Precocious puberty

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Fingerprint Dive into the research topics of 'Bicalutamide and third-generation aromatase inhibitors in testotoxicosis'. Together they form a unique fingerprint.

  • Cite this

    Lenz, A. M., Shulman, D., Eugster, E. A., Rahhal, S., Fuqua, J. S., Pescovitz, O. H., & Lewis, K. A. (2010). Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics, 126(3), e728-e733.